Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1RA). GLP-1RA activates the GLP‐1 receptor by mimicking natural GLP‐1 to enhance insulin secretion in a glucose-dependent manner, inhibit glucagon-secretion, delay gastric emptying, and reduce food intake through central appetite suppression, thereby reducing blood glucose and weight loss.
GLP-1RA not only has significant hypoglycemic effect, but also has low risk of hypoglycemia when used alone. At the same time, GLP-1RA has the effects of weight loss, blood pressure lowering and improving lipid profile, etc., so far, it has become one of the world's best-selling hypoglycemic drugs.
“Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. We can supply some Semaglutide intermediates with large quantities and the most reasonable price”, said the Marketing Chief of Huateng Pharma.
Officially recommended by guidelines for GLP-1RA
GLP-1RAs, including semaglutide, are officially recommended by national and international guidelines for their combination of glucose-lowering and cardiovascular protection benefits.
The 2020 Chinese Diabetes Society (CDS) guidelines recommend that patients with type 2 diabetes combined with ASCVD or high cardiovascular risk, regardless of whether their HbA1c reaches the target, as long as there are no contraindications, it is recommended to add GLP-1RA with evidence of ASCVD benefits on the basis of metformin.
Similarly, the hypoglycemic regimen recommended by the 2021 American Diabetes Association (ADA) standard of care also recommends that if a patient has ASCVD, or is at high risk of ASCVD, or has heart failure, or has CKD, regardless of baseline HbA1c levels, GLP-1RA can be used directly independently of metformin.
The "Expert Consensus on the Diagnosis and Treatment of Cardiovascular Diseases in Diabetic Patients" updated in May 2021 also emphasized [3] that a number of cardiovascular outcome trials (CVOT) completed in recent years found that GLP-1RA has cardiovascular protection other than hypoglycemia Therefore, for patients with T2DM and CVD, if metformin is contraindicated or intolerable, GLP-1RA with evidence of cardiovascular protection can be selected as the first-line treatment.
Huateng Pharma, as a leading pharmaceutical intermediates supplier in China, can provide CAS NO.:134979-01-4, CAS NO.:1662688-20-1, CAS NO.:1118767-16-0, CAS NO.:108466-89-3, CAS NO.:166108-71-0, CAS NO.:134978-97-5, CAS NO.:1143516-05-5 and CAS NO.:871-70-5 from lab to commercial scale, which can be used as Semaglutide intermediates. Also, we can provide CDMO services to meet your requirements, combining a high level of competencies, equipment and quality.
About Huateng Pharma
Huateng Pharma is a global provider in contract development and manufacturing for intermediates. With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.
Contact Us
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Email: sales@huatengusa.com
Website: https://us.huatengsci.com/
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818